Dr. Rita Assi, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 131
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IN license 01088860A - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Bloomington Hospital Bloomington, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Indiana University Health North Hospital Carmel, IN
- Reid Health Richmond, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 319
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 81 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 70 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 56 | 25 |
| New patient office or other outpatient visit, 45-59 minutes | 46 | 46 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Indianapolis, IN | 150 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Indianapolis, IN | 79 |
| Fluconazole Other prescribers in Indianapolis, IN | 67 |
| Prednisone Other prescribers in Indianapolis, IN | 64 |
| Ciprofloxacin Hcl Other prescribers in Indianapolis, IN | 43 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Indianapolis, IN | 33 |
| Ondansetron Hcl Other prescribers in Indianapolis, IN | 28 |
| Venclexta (venetoclax) | 26 |
| Posaconazole | 15 |
| Bosulif (bosutinib) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 14 payments worth $4,098 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $3,102 |
|---|---|
| Novartis Pharmaceuticals Corporation | $419 |
| AstraZeneca Pharmaceuticals LP | $245 |
| Taiho Oncology, Inc. | $163 |
| Janssen Biotech, Inc. | $88.72 |
| AbbVie Inc. | $49.00 |
| Genmab U.S., Inc. | $31.86 |
| Consulting Fee | $2,600 |
|---|---|
| Food and Beverage | $1,091 |
| Speaking at a medical education program | $408 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,600 |
| AstraZeneca Pharmaceuticals LP Oct 31, 2025 | Speaking at a medical education program | $245 |
| Taiho Oncology, Inc. Oct 31, 2025 | Speaking at a medical education program | $163 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $345,553 in research payments for these studies, mostly to the institutions running them.
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091865 - Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len
Genentech, Inc. - Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie Inc. · Active, not recruiting · NCT05618028
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.